Open Orphan #ORPH – FDA Breakthrough Designation for Big Pharma RSV candidate
Vaccine candidate assessed in successful human challenge trial conducted by hVIVO Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the announcement dated 14 February 2022 from Bavarian Nordic A/S (“Bavarian Nordic”) (OMX: BAVA), reporting […]
Open Orphan #ORPH – Results from the world’s first COVID-19 Characterisation Study
Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces the results from the world’s first COVID-19 characterisation study, which was a partnership between hVIVO, Imperial College London, the Vaccine Taskforce and Department of Health and Social […]
Open Orphan #ORPH – Mention in the Times Market report
https://www.thetimes.co.uk/article/jd-sports-gets-big-tick-as-nike-beats-forecasts-bnc66d60l Among smaller companies, Open Orphan struck a chord with investors. It rose 1¾p, or 7.7 per cent, to 22¾p after its hVivo subsidiary was awarded a £5 million contract to start human trials on a drug to develop protection against respiratory viral infections.
Open Orphan #ORPH – £5m Influenza human challenge study contract win
Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan plc, has signed a £5m influenza human challenge study contract with a biotech company developing an antiviral drug for protection against respiratory […]
Open Orphan #ORPH – £5.1m RSV Human Challenge Study Contract Win
Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO , a subsidiary of Open Orphan, has signed a £5.1m contract with a biopharmaceutical company to test its Investigational Medicinal Product (IMP) using hVIVO’s respiratory syncytial […]
#ORPH Open Orphan – £1.5m Contract renewal for Venn Life Sciences
Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that Venn Life Sciences (“Venn”), a subsidiary of Open Orphan, has signed a contract renewal with a major global pharmaceutical client worth £1.5m over two years. The renewed contract will commence in January 2022, with […]
Poolbeg Pharma #POLB – Exec Chairman Cathal Friel & CEO Jeremy Skillington talk to Alan Green
Poolbeg Pharma #POLB Exec Chairman Cathal Friel and CEO Jeremy Skillington talk to Alan Green about the company’s ‘capital light’ business model. We discuss the POLB 001 asset, spun out of Open Orphan #ORPH, data samples, the PredictViral and vaccine discovery platforms plus further pipeline products. Cathal discusses the company cash position, and Jeremy highlights […]
New York Times – Would You Let a Scientist Infect You With COVID?
By Kate Murphy, New York Times In an age of masking, compulsive hand sanitizing and plexiglass dividers, it seems inconceivable that for more than 40 years people enthusiastically signed up — and were often put on a waiting list — to have respiratory viruses, including coronaviruses, dripped into their noses. They were volunteers at the […]
Open Orphan #ORPH – Directorate Change
Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces the appointment of Yamin ‘Mo’ Khan as an Independent Non-Executive Director to the Board of Open Orphan with immediate effect. Mo will also Chair both the Audit and Risk and […]
Open Orphan #ORPH – Controlled Human Infection Studies Report following March Webinar
Controlled Human Infection Studies: Proposals for guidance on how to design, develop and produce a challenge strain. Report follows March Webinar run by hVIVO with HIC VAC, Wellcome Trust and IABS Highlights: Applicable local, national and regional guidelines on manufacture and use of challenge agents must be considered. As challenge agents are biological products, […]